ARA-290, also called cibinetide, is an 11-amino-acid peptide derived from erythropoietin that activates the innate repair receptor without stimulating red blood cell production. It has been studied in five published human trials, mostly in small-fiber neuropathy associated with sarcoidosis and type 2 diabetes. Across that programme, measures of nerve fiber structure improved, while pain scores generally did not separate from placebo. It is not approved by the FDA for any use.
That last paragraph is the whole article in miniature, and it is more nuanced than what most pages selling this peptide will tell you. ARA-290 is not a fringe compound with no evidence. It has a larger and better-designed human trial record than almost any peptide sold online. But the trials found something more specific than โit fixes nerve pain,โ and the difference matters if you are deciding whether to spend money on it.
How ARA-290 works
Erythropoietin, or EPO, is best known for driving red blood cell production, but it also has a second, separate job: protecting tissue after injury. Those two effects run through different receptors. Giving someone full EPO for its tissue-protective effect also thickens the blood, which is why EPO was never a practical repair drug.
ARA-290 was engineered to split those effects apart. It was designed from a region of the EPO molecule that activates only the innate repair receptor (IRR), a heteromeric receptor made up of the EPO receptor (EPOR) paired with the beta-common receptor (CD131). Activating that receptor downregulates pro-inflammatory signalling, limits oxidative stress and promotes tissue repair pathways, without triggering erythropoiesis.
In plain terms: it is the repair half of EPO, with the blood-thickening half removed by design. Every published human study confirms the second part, which is why no trial has reported a rise in haemoglobin or haematocrit.
What the human trials actually found
There are five published, peer-reviewed human trials. This is the complete list, not a selection, and the column that matters most is the last one.
| Study | Population and dosing | What improved | What did not |
|---|---|---|---|
| Heij 2012, pilot | 22 sarcoidosis patients with small-fiber neuropathy; 2ย mg intravenously three times weekly for 4 weeks | Neuropathy screening score; pain and physical function dimensions of the SF-36 | Brief Pain Inventory and fatigue improved equally in both groups; no change in depressive symptoms |
| Dahan 2013 | Sarcoidosis with documented small nerve fiber loss; daily subcutaneous injection for 28 days | Neuropathic symptoms, corneal small nerve fiber density, temperature sensitivity, 6-minute walk distance | Nothing reported as negative; this is the most favourable trial in the set |
| Brines 2015, phase 2 | Type 2 diabetes with painful neuropathy; 4ย mg subcutaneously daily for 28 days, followed 28 days more | PainDetect score, HbA1c, lipid profile; corneal nerve fiber density in those starting below normal | No safety issues identified, but this was an exploratory phase 2 with no confirmatory follow-up |
| Cerit 2015 | Human neuropsychological model of antidepressant action | Not applicable | Did not show the expected antidepressant signal; the depression indication was subsequently discontinued |
| Culver 2017, phase 2b | 64 patients, sarcoid small nerve fiber loss with neuropathic pain; 1, 4 or 8ย mg daily for 28 days versus placebo | Corneal nerve fiber area at 4ย mg (placebo-corrected +697ย ยตmยฒ, Pย =ย 0.012); regenerating GAP-43-positive skin fibers at 4ย mg (Pย =ย 0.035) | Pain. It improved in every group including placebo, and the placebo-corrected difference at 4ย mg was Pย =ย 0.157, which is not statistically significant. The 1ย mg and 8ย mg doses missed the primary endpoint too |
The honest reading: structure moved, pain did not
Put the two sarcoidosis trials side by side and a consistent pattern appears. In the 2012 pilot, the neuropathy screening score separated from placebo but the Brief Pain Inventory improved identically in both arms. In the 2017 phase 2b, the nerve fiber endpoints separated from placebo convincingly, and the pain endpoint did not.
Twice, in the same condition, measured nerve structure responded and reported pain did not. That is not a failed drug. Regrowing small nerve fibers is a meaningful biological effect, and the Culver investigators concluded it was consistent with disease modification. But it is a very different claim from the one made on most pages selling this peptide, which cite these same trials as evidence that ARA-290 relieves nerve pain. Read the papers they are citing and the pain result is the one that did not reach significance.
Why would pain and structure diverge? Chronic neuropathic pain involves central sensitisation as well as peripheral nerve damage, so repairing the peripheral fibers does not automatically quiet a pain signal the nervous system has already learned. Twenty-eight days is also a short window in which to expect a structural change to translate into a symptom change. Both are plausible, and neither has been tested, because the trial that would test it was never run.
More is not better: what the dose-response showed
This is the single most practically useful finding in the whole literature, and it is almost never mentioned.
Culver 2017 tested three doses against placebo. Only the middle one worked. The placebo-corrected change in corneal nerve fiber area was not significant at 1ย mg, significant at 4ย mg, and not significant again at 8ย mg, where the confidence interval crossed zero. Doubling the dose above 4ย mg did not double the effect. It lost the effect.
Receptor pharmacology offers a reason: bell-shaped dose-response curves are well described for cytoprotective signalling, where receptor occupancy beyond an optimum can desensitise rather than amplify. Whatever the mechanism, the empirical result stands, and it directly contradicts the escalating protocols circulating on peptide forums. If you are reading a protocol that tells you to work up from 4ย mg to 8ย mg or beyond, it is recommending the dose that failed the primary endpoint in the only trial that tested it.
What the trials used, and why that is not a prescription
People searching for an ARA-290 protocol generally want a number. Here is what the published trials used, which is a factual record rather than a recommendation:
- 2ย mg intravenously, three times weekly for 4 weeks in the 2012 sarcoidosis pilot.
- 4ย mg subcutaneously, once daily for 28 days in the 2015 diabetes trial and as the effective arm of the 2017 phase 2b.
- 1ย mg and 8ย mg daily were also tested in 2017, and both missed the primary endpoint.
Three things follow from that list. First, there is no established clinical dose, because there is no approved indication; what exists are investigational regimens run under medical supervision for a fixed 28-day window. Second, every trial stopped at 28 days, so nobody has published what happens on month three, month six or year one. Third, the route changed between the pilot and the later work, from intravenous to subcutaneous, and the subcutaneous daily schedule is what the larger trials standardised on.
On reconstitution and injection technique, which are among the most-searched ARA-290 questions: in a supervised setting that is handled by the clinic, not by the patient working from a forum post. Lyophilised peptide reconstituted incorrectly can be underdosed, overdosed, or contaminated, and sterile technique is not something to learn from a video. If you are being sold a vial with instructions to reconstitute it yourself, you are not in a supervised setting.
Where ARA-290 stands with regulators
It is not FDA-approved, in the United States or anywhere else, for any indication.
It sits in FDA 503A Category 3. The FDA maintains three categories for bulk drug substances nominated for use in pharmacy compounding, and as of the agencyโs list updated 14 May 2026, cibinetide (ARA-290) is listed under Category 3: Bulk Drug Substances Nominated Without Adequate Support. Category 3 is worth understanding precisely, because it is not the same as Category 2. Category 2 is for substances that raise significant safety risks. Category 3 means the nomination did not include enough supporting information for the FDA to evaluate the substance at all. It is a paperwork verdict, not a safety verdict, but the practical consequence is the same: a compound in Category 3 is outside the agencyโs interim non-enforcement policy. For contrast, GHK-Cu sits in Category 1, under active evaluation, and the FDA has said it intends to consult its Pharmacy Compounding Advisory Committee about it. ARA-290 has no equivalent process under way.
Development has stopped. ClinicalTrials.gov lists four registered studies of cibinetide in total. None is recruiting, none is active, there has never been a phase 3, and the most recently registered trial, a study in diabetic macular oedema in Belfast, is marked terminated. A compound with genuinely promising phase 2b data would normally be in phase 3 by now. It is not, and the reason appears to be commercial rather than scientific.
It is prohibited in sport at all times. This one catches people out, because ARA-290 is not named individually on the World Anti-Doping Agency list. It does not need to be. WADA section S2.1.5 covers innate repair receptor agonists, giving asialo EPO and carbamylated EPO as examples, and the preamble to section S2 states that the listed substances โand other substances with similar chemical structure or similar biological effect(s)โ are prohibited. ARA-290 is an innate repair receptor agonist by definition, since that is its entire designed mechanism. Any drug-tested athlete should treat it as banned and confirm with their anti-doping organisation.
Safety, and the limits of what is known
Within the trials, the safety record is reassuring as far as it goes. The 2012 pilot reported no safety concerns on clinical or laboratory assessment. The 2015 phase 2 identified no potential safety issues across 56 days of observation. Because the molecule does not activate the classical EPO receptor pathway for erythropoiesis, the haematocrit rise that makes EPO itself dangerous has not been observed.
The limits are equally clear, and they are limits of evidence rather than findings of harm:
- Roughly 170 people have received ARA-290 in published trials. That is a reasonable phase 2 total and far too small to detect uncommon adverse events.
- No study has run longer than 28 days of dosing. There is no published long-term safety data of any kind.
- Local injection-site reactions are the expected nuisance effect of any daily subcutaneous peptide, including bruising, redness and transient tenderness.
- Material bought online is of unverified identity, purity and sterility. Most ARA-290 sold on the internet is labelled โresearch use onlyโ, which is a legal formula, not a quality standard.
Who should not consider ARA-290
- Anyone who has not had their neuropathy worked up. Burning or numb feet can reflect diabetes, B12 deficiency, thyroid disease, alcohol, chemotherapy, autoimmune disease or nerve compression, and several of those have specific treatments that work. Reaching for an investigational peptide before the cause is known is the wrong order of operations. A diagnostic blood panel usually comes first.
- Anyone with an active malignancy or a recent cancer history. The receptor family involved is also implicated in cell survival signalling, and no trial has enrolled oncology patients. There is no safety data here either way, which is itself the reason to be cautious.
- Drug-tested athletes, per the WADA section above.
- During pregnancy or breastfeeding, and in anyone under 18. Neither group has been studied.
- Anyone expecting pain relief as the outcome, given that pain is the endpoint the trials did not deliver.
How ARA-290 compares with other peptides on the menu
It is worth being clear about what ARA-290 is and is not within the peptide category. It is not a growth hormone secretagogue and has nothing to do with body composition. It is not a nootropic in the way dihexa is positioned, since no cognitive endpoint has been studied and the one neuropsychiatric trial was negative. Its closest conceptual neighbour is BPC-157, in that both are framed around tissue repair, but the evidence profiles are inverted: BPC-157 has a large animal literature and almost no human trial data, whereas ARA-290 has a modest animal literature and five published human trials, including a randomised phase 2b that hit its primary endpoint.
Among the compounds sold as research peptides, ARA-290 has an unusually strong human evidence base. That is the fair summary, and it sits alongside the equally fair summary that its most commercially attractive claim, pain relief, is the one its own trials failed to establish.
Frequently asked questions
What is ARA-290 used for?
In published research it has been studied for small-fiber neuropathy associated with sarcoidosis and with type 2 diabetes, and in single trials for diabetic macular oedema and as a candidate antidepressant. It has no approved use in any country. At a clinic it is considered only after a consultation, as part of a wider plan for nerve symptoms, and never as a stand-alone treatment for a diagnosed disease.
What dose was used in the ARA-290 studies?
The larger trials used 4ย mg subcutaneously once daily for 28 days. The 2012 pilot used 2ย mg intravenously three times a week for four weeks. The 2017 phase 2b also tested 1ย mg and 8ย mg, and both missed the primary endpoint, so a higher dose is not a better one. These are study protocols, not a dosing recommendation, and there is no established clinical dose because there is no approved indication.
Does ARA-290 help nerve pain?
The honest answer is that the trials did not show it. In the 2017 phase 2b, pain improved in every arm including placebo, and the placebo-corrected difference at the effective dose was not statistically significant. In the 2012 pilot, the Brief Pain Inventory improved equally in the treated and placebo groups. What did improve, measurably and repeatedly, was nerve fiber density and area. Anyone promising pain relief on the strength of these studies is describing a result the studies did not produce.
How is ARA-290 given, and would I reconstitute it myself?
In the trials it was given by daily subcutaneous injection, after the pilot study moved on from intravenous dosing. In a supervised clinical setting, reconstitution and preparation are handled by the clinic. Self-reconstituting lyophilised peptide from an unregulated supplier introduces dosing error and contamination risk, and a product sold with self-preparation instructions should be treated as a warning sign rather than a convenience.
Is ARA-290 FDA approved?
No. It is not approved for any indication, and it is listed in FDA 503A Category 3, meaning it was nominated for use in pharmacy compounding without adequate supporting information for the agency to evaluate it. There is no active clinical trial programme and no phase 3 study has ever been conducted.
Is ARA-290 banned in sport?
Yes, treat it as banned. It is not named individually on the WADA Prohibited List, but section S2.1.5 prohibits innate repair receptor agonists, and section S2 extends to substances with similar chemical structure or biological effect. ARA-290 was purpose-built as an innate repair receptor agonist, so it falls inside that class. Competing athletes should confirm with their own anti-doping organisation before using anything in this category.
Important medical disclaimer
These statements have not been evaluated by the Food and Drug Administration. ARA-290 (cibinetide) is not an FDA-approved drug and is not approved in the United States or any other country for any indication. It appears on the FDAโs 503A list under Category 3, bulk drug substances nominated without adequate support. This article is educational and is not medical advice, not a substitute for evaluation by a qualified clinician, and not a claim that ARA-290 diagnoses, treats, prevents or cures any condition, including neuropathy, sarcoidosis, diabetes or any pain syndrome. Dosing figures quoted are the regimens used in published clinical trials, reported for accuracy, and are not recommendations. Peripheral neuropathy requires medical diagnosis, because the underlying cause determines the appropriate treatment and several causes are reversible. ARA-290 has not been studied in pregnancy, breastfeeding, people under 18, or people with active malignancy. It is prohibited in competitive sport. Any peptide is dispensed at Robertson Wellness and Aesthetics only after a consultation with a licensed clinician, and availability is subject to current FDA compounding regulations.
Sources referenced
Heij L, Niesters M, Swartjes M, et al. โSafety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study.โ Molecular Medicine, 2012;18(1):1430-1436. ยท Dahan A, Dunne A, Swartjes M, et al. โARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density.โ Molecular Medicine, 2013;19(1):334-345. ยท Brines M, Dunne AN, van Velzen M, et al. โARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes.โ Molecular Medicine, 2015;20(1):658-666. ยท Cerit H, Veer IM, Dahan A, et al. โTesting the antidepressant properties of the peptide ARA290 in a human neuropsychological model of drug action.โ European Neuropsychopharmacology, 2015;25(12):2289-2299. ยท Culver DA, Dahan A, Bajorunas D, et al. โCibinetide improves corneal nerve fiber abundance in patients with sarcoidosis-associated small nerve fiber loss and neuropathic pain.โ Investigative Ophthalmology & Visual Science, 2017;58(6):BIO52-BIO60. ยท van Velzen M, Heij L, Niesters M, et al. โARA 290 for treatment of small fiber neuropathy in sarcoidosis.โ Expert Opinion on Investigational Drugs, 2014;23(4):541-550. ยท US Food and Drug Administration, โBulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act,โ categories list updated 14 May 2026. ยท World Anti-Doping Agency, Prohibited List, section S2.1.5, innate repair receptor agonists. ยท ClinicalTrials.gov registry entries for cibinetide, including NCT02039687 and NCT06626971.
Medically reviewed by Biana Borchenko, FNP-BC (A4M), Robertson Wellness and Aesthetics, Beverly Hills.
